Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03765073 · ClinicalTrials.gov registry record · Phase 2
Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,208
- Enrollment target
NCT03765073 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,208 participants.
The verdict
NCT03765073, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,208 participants
- Enrollment target
Study Summary
Phase 1/2, randomized, placebo-controlled, observer-blinded study will evaluate the safety, tolerability and immunogenicity of the investigational multivalent group B streptococcus vaccine administered at one dose level (various formulations) in healthy nonpregnant women (various formulations at one dose level), and then in healthy pregnant women (various formulations at three dose levels), and finally in healthy pregnant women at a selected dose level/formulation.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Multivalent Group B streptococcus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03765073
The ClinicalTrials.gov registry entry for NCT03765073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03765073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03765073 about?
NCT03765073 is a clinical study titled "Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants". Phase 1/2, randomized, placebo-controlled, observer-blinded study will evaluate the safety, tolerability and immunogenicity of the investigational multivalent group B streptococcus vaccine administered at one dose level (various formulations) in healthy nonpregnant women (various formulations at one...
What is the current status of trial NCT03765073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,208 participants. The study started on 2019-01-14. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT03765073?
The interventions under investigation include: Placebo (BIOLOGICAL), Multivalent Group B streptococcus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03765073?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.